Rhythm Pharmaceuticals, Inc.
RYTM
Rang in Aktien
#3017
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Aktienkurs
$88.37
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$6.08B
Veränderung (1 Tag)
2.55%
Veränderung (1 Jahr)
-21.37%
Land
US
Handel Rhythm Pharmaceuticals, Inc. (RYTM)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Rhythm Pharmaceuticals, Inc. (RYTM)
Anzahl der ausstehenden Aktien zum June 2026: 68.59M
Laut den neuesten Finanzberichten und dem Aktienkurs von Rhythm Pharmaceuticals, Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 68.59M. Am Ende von December 2023 hatte das Unternehmen 57.67M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Rhythm Pharmaceuticals, Inc. (RYTM) von 2012 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 68.59M | 12.46% |
| 2024 | 61.00M | 5.76% |
| 2023 | 57.67M | 10.65% |
| 2022 | 52.12M | 5.08% |
| 2021 | 49.60M | 12.40% |
| 2020 | 44.13M | 21.15% |
| 2019 | 36.42M | 17.48% |
| 2018 | 31.00M | 15.99% |
| 2017 | 26.73M | 59.77% |
| 2016 | 16.73M | 64.07% |
| 2015 | 10.20M | 0.00% |
| 2014 | 10.20M | -79.72% |
| 2013 | 50.27M | 0.00% |
| 2012 | 50.27M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | 270.16% |
US
|
|
| 396.00M | 477.32% |
US
|
|
| 478.91M | 598.20% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -9.34% |
NL
|
